Dual-Tracer 68Ga-PSMA and 68Ga-DOTATATE PET/CT in Advanced Prostate Cancer: Persistent PSMA Expression Despite Clinically Suspected Treatment-Emergent Neuroendocrine Differentiation
Clinical Genitourinary Cancer
· Elsevier
The publisher did not provide an abstract — full text is available via the link below.
Read at publisher →
Cite
Get new articles on “Urology”
Subscriptions, keyword tracking and favourites — in the Articlium Telegram bot.
Open in Telegram
Citation
✕
ГОСТ
APA
MLA
BibTeX
Dual-Tracer 68Ga-PSMA and 68Ga-DOTATATE PET/CT in Advanced Prostate Cancer: Persistent PSMA Expression Despite Clinically Suspected Treatment-Emergent Neuroendocrine Differentiation. // Clinical Genitourinary Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1558767326001655?dgcid=rss_sd_all
Dual-Tracer 68Ga-PSMA and 68Ga-DOTATATE PET/CT in Advanced Prostate Cancer: Persistent PSMA Expression Despite Clinically Suspected Treatment-Emergent Neuroendocrine Differentiation. Clinical Genitourinary Cancer. https://www.sciencedirect.com/science/article/pii/S1558767326001655?dgcid=rss_sd_all
“Dual-Tracer 68Ga-PSMA and 68Ga-DOTATATE PET/CT in Advanced Prostate Cancer: Persistent PSMA Expression Despite Clinically Suspected Treatment-Emergent Neuroendocrine Differentiation.” Clinical Genitourinary Cancer.
@article{article40875,
title = {Dual-Tracer 68Ga-PSMA and 68Ga-DOTATATE PET/CT in Advanced Prostate Cancer: Persistent PSMA Expression Despite Clinically Suspected Treatment-Emergent Neuroendocrine Differentiation},
journal = {Clinical Genitourinary Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1558767326001655?dgcid=rss_sd_all}
}